Induction of γ-globin mRNA, erythroid differentiation and apoptosis in UVA-irradiated human erythroid cells in the presence of furocumarin derivatives

Resveratrol: Antioxidant activity and induction of fetal hemoglobin in erythroid cells from normal donors and β-thalassemia patients

“…However, there is scant information regarding the potential use of such products for the treatment of the β-hemoglobinopaties, β-thalassemia and sickle-cell anemia (SCA). The most complete of the reports of such compounds deal with mithramycin (14,15), rapamycin (16)(17)(18) and psoralens (19)(20)(21)(22). Resveratrol (3,5,4' -trihydroxystilbene, 'E' form) (23)(24)(25)(26)) is a natural phytoalexin present in the skin of grapes (50-100 µg/mg) and in red wine (1.3-3 mg/l) (24).…”

Erythroid Induction of Chronic Myelogenous Leukemia K562 Cells Following Treatment with a Photoproduct Derived from the UV‐A Irradiation of 5‐Methoxypsoralen

“…However, the percentage of benzidine-positive cells is still significant with respect to the control. Commonly, there is an erythroid differentiation maximum (see Viola et al [19] for an example), which could be explained by a decrease in cell survival after long incubation period. Erythroid differantiation did not seem to depend on UV-A doses because there were only small differences between them in term of benzidine-positive cells.…”

“…[14] We have recently demonstrated that the combination of psoralens with UV-A light is highly effective in inducing erythroid differentiation in different cellular models. [19][20] However, the eventual use of these compounds in PUVA therapy could encounter some problems, such as the use of the invasive photopheresis techniques and side effects such as phototoxiInduction of terminal erythroid differentiation can be an efficient strategy to inhibit proliferation of chronic myelogenous leukemia cells. Psoralens, well-known photo-chemotherapeutic agents, were found to be efficient at inducing erythroid differentiation of K562 cells, an in vitro cell line isolated from the pleural effusion of a patient with chronic myelogenous leukemia in blast crisis.…”

“…[6,7] This cell line has been proposed as a very useful experimental system to identify antitumor compounds [8,9] acting by inducing terminal erythroid differentiation. [10][11][12][13][14][15][16][17][18] The K562 cell line contains a low proportion of hemoglobin (Hb)-synthesizing cells under standard, cell-growth conditions, but are able to undergo terminal erythroid differentiation when treated with a variety of compounds, including short fatty acids, [10] 5-azacytidine, [10] tallimustine, [12,13] cisplatin and cisplatin analogues, [14] mithramycin and chromomycin, [15,16] rapamycin, [17] everolimus, [18] psoralens [19][20] and resveratrol. [21] Following erythroid induction, a sharp increase in the expression of human e and g globin genes is observed in K562 cells, leading to cytoplasmic accumulation of Hb Portland (z 2 g 2 ) and Hb Gower 1 (z 2 e 2 ).…”

Synthesis and Cytotoxic Activity of a New Group of Heterocyclic Analogues of the Combretastatins

“…In last decades many new potential therapeutic applications for furocoumarins are found. For instance, some psoralen derivatives were found to induce erythroid differentiation in different cellular models [16,17]. Moreover it was shown that annelation of a cyclopentane, cyclohexane, benzene, or pyridazine ring to the furan ring in the psoralen skeleton changed the phototoxicity and, in some cases led to a marked increase in the photo-antiproliferative activity [18].…”